From humble beginnings in 1983, Sun Pharma has grown into a leading specialty generic company worldwide and the No. 1 pharmaceutical company in India. The company has pursued strategic growth through significant acquisitions, including Ranbaxy, Taro Pharmaceuticals, and the March 2025 acquisition of Checkpoint Therapeutics. Sun Pharma invests 6–8% of global revenues annually into Research and Development with a team of over 2,900 R&D personnel, strengthening its position in complex and differentiated formulations.
Cyborg Score Rationale
Current market capitalization of Sun Pharmaceutical Industries is $45.1B with strong global scale and diversification. However, earnings have been going backwards lately while most other companies have been seeing positive earnings growth, and many expect the dour earnings performance to recover substantially. The company maintains strategic positioning but faces near-term headwinds.
Top Insights
FY 2024-25 revenue of ₹520 billion (up 9.0% YoY) with global specialty revenue rising 17.1% to $1,216 million (~20% of total revenue)
March 2025 acquisition of Checkpoint Therapeutics for $355 million strengthens oncology and immunotherapy pipeline
In the U.S., Sun Pharma is amongst the leading specialty generic companies and ranked No. 2 in generic dermatology by prescriptions
In 2025 Sun Pharma was included in the S&P Global Sustainability Yearbook, placing it among the top 5% of pharmaceutical companies globally